Answers are grounded in this paper and cite their sources.
Shows enhanced wound healing in diabetic models, indicating improved glucose management and tissue recovery.
Diabetic wounds are characterized by persistent oxidative stress, chronic inflammation, and impaired angiogenesis driven by hyperglycemia. Here, we developed a glucose-responsive nanozyme hydrogel (MNP@D-CH) composed of moslosooflavone-loaded, polydopamine-coated PLGA nanoparticles embedded in a dynamic network of phenylboronic acid-modified chitosan and dopamine-conjugated hyaluronic acid crosslinked via reversible boronate esters. Under high glucose, the hydrogel disassembles to release nanoparticles on demand. In vitro, MNP@D-CH eliminated > 90 % of reactive oxygen species, doubled fibroblast migration, restored endothelial tube formation to levels comparable to recombinant human VEGF, downregulated pro-inflammatory cytokines (Il6, Il1b, Tnf), and upregulated Vegfa. It also inhibited 90–100 % of Escherichia coli and Staphylococcus aureus . In diabetic mice, the hydrogel achieved 95.67 % wound closure by day 14, significantly outperforming non-responsive controls and a commercial growth factor, with enhanced re-epithelialization, granulation tissue formation, and collagen organization. RNA sequencing revealed that the treatment suppressed IL-17 signaling and activated the PI3K-Akt pathway. These findings demonstrate that a single hydrogel integrating glucose responsiveness, nanozyme-mediated antioxidation, and controlled drug release can effectively overcome the multiple barriers to diabetic wound healing.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: